Search

Your search keyword '"Cho, Hearn J."' showing total 218 results

Search Constraints

Start Over You searched for: Author "Cho, Hearn J." Remove constraint Author: "Cho, Hearn J."
218 results on '"Cho, Hearn J."'

Search Results

2. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

3. Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma

4. Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

5. Interventions and outcomes of patients with multiple myeloma receiving salvage treatment after BCMA-directed CAR T therapy

6. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

7. Abstract CT262: Durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial

8. Data from Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma

9. Supplementary Data from Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma

11. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

12. Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

13. Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

15. Extramedullary Relapse Post CAR-T

16. Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

17. Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment

18. Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

19. Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

20. The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

21. Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

22. Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.

26. Bispecific Antibodies in Multiple Myeloma: Present and Future

27. Abstract 868: Heritable cancer mutations in multiple myeloma

28. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

29. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma

30. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer

31. Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m 2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m 2

33. The myeloma-developing regimens using genomics (MyDRUG) master protocol.

35. Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma

36. Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.

37. Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM).

38. Melanoma and immunotherapy bridge 2015

39. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma

40. A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.

41. Phase 1 study to evaluate the safety and efficacy of immunotherapy with tremelimumab and durvalumab in multiple myeloma patients receiving high dose chemotherapy and autologous stem cell transplant (HDT/ASCT) + peripheral blood lymphocyte (PBL) reinfusion.

44. Structures of Two Melanoma-Associated Antigens Suggest Allosteric Regulation of Effector Binding

47. Early detection of CRS after CAR-T therapy using wearable monitoring devices: Preliminary results in relapsed/refractory multiple myeloma (RRMM).

48. Abstract LB-116: Strong MAGE-A3-specific humoral and cellular immune responses in multiple myeloma patients receiving MAGE-A3 protein immunotherapy and peripheral blood lymphocyte reconstitution

49. A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

50. Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Catalog

Books, media, physical & digital resources